Zimbabwe has turned down a major American healthcare agreement worth $367m (£272m) spanning five years due to Washington's demand for confidential information.
This rejection was revealed after a internal memorandum from December was disclosed, revealing that President Emmerson Mnangagwa believed the arrangement was "skewed".
A government representative has since stated that the US was requesting health data for scientific study and commercial purposes but was unwilling to guarantee the benefits from future treatments.
"We must now begin the challenging and unfortunate task of winding down our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had donated over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for further negotiations to find a deal suitable to both sides so the nation's vital HIV treatment initiative can proceed.
Broader Background
Zimbabwe's decision follows a comparable situation in neighbouring Kenya, where a court halted a similar deal with the US following legal challenges were filed about the safety of citizens' health data.
After returning to office last year, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
USAID had administered assistance for the American government, but Trump stated its expenditure was "inefficient" and his administration was seeking direct bilateral agreements to boost transparency and accountability.
As per statements, Sixteen African countries have so far agreed to these new health pacts, constituting more than $18.3bn of fresh investment.
Specifics of the Declined Agreement
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration might have yielded immense advantages for Zimbabwean communities, particularly the 1.2 million currently on HIV treatment through American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Our nation was requested to share its genetic material and health information indefinitely, with no equivalent assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that could result from that provided information," he stated.
"In essence, our country would provide the basic resources for medical research without any certainty that the final treatments would be accessible to our population should a new pandemic arise."
Sovereignty and International Frameworks
Mangwana further noted that the American exit from the global health body and its pursuit of bilateral health agreements were upending systems previously set up via the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system designed to deal with future pandemics.
"This framework is intended to guarantee that when a nation contributes its information, the benefits – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the capability to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We encourage further dialogue with our US partners on how future collaboration might be structured in a manner that respects the independence and interests of each country."
Health Experts Reaction
Medical experts stated it understood the government's concerns, but recommended that negotiations should continue given that much of the nation's Aids initiatives depended on international support.
"In cases where technical issues exist, such as those relating to data governance or implementation frameworks, these can often be addressed through technical clarification and mutually agreed protections," the group added.
The situation highlights the complex tensions between accepting vital foreign assistance and protecting a country's data in an increasingly data-driven world.